NL-OMON44738已完成3 期
A Prospective, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of BAY 41-6551 as Adjunctive Therapy in Intubated and Mechanically-Ventilated Patients with Gram-Negative Pneumonia - BAY 41-6551 in Intubated and Mechanically-Ventilated Pneumonia Patients
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- Bayer
- 入组人数
- 9
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •Patients of age 18 and older, who are hospitalized, have pneumonia suspected or confirmed to be caused by Gram-negative organisms, and who are intubated and mechanically-ventilated will be selected for this study. In all patients where the pathogen is suspected of being Gram-negative, it should be confirmed as soon as culture results are available. Patients with microbiologically-confirmed pneumonia are those who have a Gram-negative organism cultured from an appropriate respiratory tract specimen collected prior to enrollment. The main inclusion criteria are:
- •Males and non-pregnant, non-lactating females, 18 years of age or older
- •Intubated and mechanically-ventilated
- •Diagnosis of pneumonia defined as presence of a new or progressive infiltrate(s) on chest radiograph
- •Presence of Gram-negative organism(s) indicated by Gramstain, or culture of pre-therapy respiratory specimen, or suspected Gram-negative pathogen
- •Impaired oxygenation
- •Clinical Pulmonary Infection Score (CPIS) * 6
- •The presence of a MDR organism in a pre-therapy respiratory
- •specimen OR at least two risk factors for MDR organisms
排除标准
- •The main exclusion criteria are:
- •* A history of hypersensitivity to amikacin, or other
- •aminoglycosides,
- •* Has received systemic Gram-negative antibiotic therapy for greater than 48 hours at the time of administration of first dose of study drug. There should be as minimal a time delay as possible between randomization and first dose of study drug but up to 48 hours will be acceptable.
- •Exception: Systemic antibiotic therapy for more than 48 hours for gram-negative infection prior to administration of first dose of study drug is permitted if the infection is caused by pathogens that are resistant to the antimicrobial agent(s) used, or the patient*s pneumonia is worsening.
- •* Has primary lung cancer (including patients with small cell lung carcinoma/non-small cell lung carcinoma and patients with unknown histology) or another malignancy metastatic to
- •the lungs or other known endobronchial obstructions.
- •Exception: Please note that patients with complete resection of non-small cell lung carcinoma are eligible for the study.
- •* Known or suspected active tuberculosis, cystic fibrosis, human immunodeficiency virus (HIV) infection with CD 4 count
- •200 cell/mm3, or invasive fungal infection of the lung, lung abscess, or empyema
- •* Known or suspected bacteremia secondary to Staphylococcus
- •* Known or suspected neuromuscular disorders such as myasthenia gravis or parkinsonism
- •* Has had a stroke within five days
- •* A positive urine and/or serum beta-human chorionic gonadotropin (*-hCG) pregnancy test
- •* Burns greater than 40% of total body surface area
- •* Patients with a serum creatinine * 2 mg/dL (177 *mol/L)
- •Exception: Patients with a serum creatinine * 2 mg/dL (177 *mol/L) and being treated with continuous renal replacement therapy (continuous veno-venous hemofiltration [CVVH] and continuous veno-venous hemofiltration with dialysis[CVVH-D]) or daily hemodialysis will receive the
- •aerosol study drug treatment (Section 8.4.6.1)
- •* Neutropenia (Screening absolute neutrophil count [ANC] * 103 neutrophils/mm3)
- •* Has been on mechanical ventilation for * 28 days
- •* Is participating in or has participated in other investigational interventional studies within the last 28 days prior to study treatment
- •* The risk of rapidly fatal illness and death within 72 hours, or any concomitant conditions not related to VAP that, in the opinion of the investigator, precludes completion of study evaluations and the course of therapy
- •* Stem cell transplantation
- •* Patients with documented Legionella infection (eg, Legionella pneumonia)
- •* Has an Acute Physiology and Chronic Health Evaluation II (APACHE II) score < 10
- •* Patients receiving veno-venous extracorporeal circulation membrane oxygenation (V-V ECMO)
研究者
相似试验
进行中（未招募）
1 期
A study to test the safety and effectiveness of Bay 41-6551 as additional therapy to standard of care antimicrobial treatment in patients who have Gram-Negative Pneumonia and are intubated and mechanially ventilated.Gram-negative pneumoniaMedDRA version: 17.1Level: LLTClassification code 10035701Term: Pneumonia gram-negative bacterial NOSSystem Organ Class: 100000004862EUCTR2008-000906-35-BEBayer Healthcare AG662
进行中（未招募）
1 期
A Prospective, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group,Multicenter Study of the Efficacy and Safety of Dapoxetine in Men With PrematureEjaculation and Concomitant Erectile Dysfunction Treated With aPhosphodiesterase-5 Inhibitor - COUPLEPremature ejaculationEUCTR2009-013616-12-FRJanssen-Cilag International NV, Turnhoutseweg 30, 2340 Beerse, Belgium
进行中（未招募）
1 期
A study to test the safety and effectiveness of Bay 41-6551 as additional therapy to standard of care antimicrobial treatment in patients who have Gram-Negative Pneumonia and are intubated and mechanially ventilated.Gram-negative pneumoniaMedDRA version: 20.1 Level: LLT Classification code 10035701 Term: Pneumonia gram-negative bacterial NOS System Organ Class: 100000004862EUCTR2008-000906-35-PTBayer AG712
进行中（未招募）
1 期
A Prospective, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of BAY 41-6551 as Adjunctive Therapy in Intubated and Mechanically-Ventilated Patients with Gram-Negative PneumoniaGram-negaive pneumoniaEUCTR2008-000906-35-CZBayer Schering Pharma AG712
进行中（未招募）
1 期
A study to test the safety and effectiveness of Bay 41-6551 as additional therapy to standard of care antimicrobial treatment in patients who have Gram-Negative Pneumonia and are intubated and mechanially ventilated.Gram-negative pneumoniaMedDRA version: 20.1Level: LLTClassification code 10035701Term: Pneumonia gram-negative bacterial NOSSystem Organ Class: 100000004862EUCTR2008-000906-35-NLBayer AG362